KR920002539A - 콜레스테롤 생합성 억제제로서의 신규 피페리딜 에테르 및 티오에테르 - Google Patents

콜레스테롤 생합성 억제제로서의 신규 피페리딜 에테르 및 티오에테르 Download PDF

Info

Publication number
KR920002539A
KR920002539A KR1019910012672A KR910012672A KR920002539A KR 920002539 A KR920002539 A KR 920002539A KR 1019910012672 A KR1019910012672 A KR 1019910012672A KR 910012672 A KR910012672 A KR 910012672A KR 920002539 A KR920002539 A KR 920002539A
Authority
KR
South Korea
Prior art keywords
group
compound
integer
double bonds
alkyl group
Prior art date
Application number
KR1019910012672A
Other languages
English (en)
Other versions
KR100225764B1 (ko
Inventor
루이스 바르니 샬로트
레이 맥카티 제임스
우드스 워너메이커 마리온
Original Assignee
게리 디. 스트리트
메렐 다우 파마슈티칼스 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디. 스트리트, 메렐 다우 파마슈티칼스 인크 filed Critical 게리 디. 스트리트
Publication of KR920002539A publication Critical patent/KR920002539A/ko
Application granted granted Critical
Publication of KR100225764B1 publication Critical patent/KR100225764B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

콜레스테롤 생합성 억제제로서의 신규 피페리딜 에테르 및 티오에테르
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 하기 일반식의 화합물.
    상기 식 중 Y는 산소원자, 황원자, 술피닐기 또는 술로닐기이고, A는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이며, B는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이고, v는 정수 0,1 또는 2이며, R은 히드록시가, C1-C4알킬기 또는 하기식의 기
    (여기서, n은 정수 0,1,2 또는 3이고, R1, R2및 R3은 각각 독립적으로 수소원자 또는 C1-C4알킬기임)이다.
  2. 치료가 필요한 환자에게 콜레스테롤 생합성 억제 유효량의 하기 일반식의 화합물을 투여하는 것으로 이루어지는 환자의 콜레스테롤 생합성을 억제시키는 방법.
    상기 식 중 Y는 산소원자, 황원자, 술피닐기 또는 술로닐기이고, A는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이며, B는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이고, v는 정수 0,1 또는 2이며, R은 히드록시기,, C1-C4알킬기 또는 하기식의 기
    (여기서, n은 정수 0,1,2 또는 3이고, R1, R2및 R3은 각각 독립적으로 수소원자 또는 C1-C4알킬기임)이다.
  3. 치료가 필요한 환자에게 혈중 콜레스테롤 강하 유효량의 하기 일반식의 화합물을 투여하는 것으로 이루어지는 환자의 혈장 콜레스테롤을 저하시키는 방법.
    상기 식 중 Y는 산소원자, 황원자, 술피닐기 또는 술포닐기이고, A는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이며, B는 0 내지 3개의 이중결합을 갖는 C2-C15알킬기이고, v는 정수 0,1 또는 2이며, R은 히드록시가, C1-C4알킬기 또는 하기식의 기
    (여기서, n은 정수 0,1,2 또는 3이고, R1, R2및 R3은 각각 독립적으로 수소원자 또는 C1-C4알킬기임)이다.
  4. 환자에게 혈중 콜레스테롤 강하 유효량의 하기 일반식의 화합물을 투여하는 것으로 이루어지는, 과콜레스테롤 혈증으로 고생하는 환자를 치료하는 방법.
    상기 식 중 Y는 산소원자, 황원자, 술피닐기 또는 술로닐기이고, A는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이며, B는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이고, v는 정수 0,1 또는 2이며, R은 히드록시가, C1-C4알킬기 또는 하기식의 기
    (여기서, n은 정수 0,1,2 또는 3이고, R1, R2및 R3은 각각 독립적으로 수소원자 또는 C1-C4알킬기임)이다.
  5. 불활성 담체의 혼합물 형태로 있거나 또는 달리 연관성 있는 형태로 있는 분석 가능한 양의 하기 일반식의 화합물로 이루어지는 조성물.
    상기 식 중 Y는 산소원자, 황원자, 술피닐기 또는 술포닐기이고, A는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이며, B는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이고, v는 정수 0,1 또는 2이며, R은 히드록시기, C1-C4알킬기 또는 하기식의 기
    (여기서, n은 정수 0,1,2 또는 3이고, R1, R2및 R3은 각각 독립적으로 수소원자 또는 C1-C4알킬기임)이다.
  6. 1종 이상의 제약학적 허용되는 담체 또는 부형재와 혼합물 형태로 있거나 또는 달리 연관성 있는 형태로 있는 혈중 콜레스테롤 강하 유효량의 하기 일반식의 화합물로 이루어지는 제약 조성물.
    상기 식 중 Y는 산소원자, 황원자, 술피닐기 또는 술포닐기이고, A는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이며, B는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이고, v는 정수 0,1 또는 2이며, R은 히드록시가, C1-C4알킬기 또는 하기식의 기
    (여기서, n은 정수 0,1,2 또는 3이고, R1, R2및 R3은 각각 독립적으로 수소원자 또는 C1-C4알킬기임)이다.
  7. 제1항에 있어서, 화합물이 2-(1-피페리딜)펜틸 이소펜틸 술피드인 화합물.
  8. 제1항에 있어서, 화합물이 2-(1-피페리딜)펜틸 이소펜틸 술폭시드인 화합물.
  9. 제1항에 있어서, 화합물이 2-(1-피페리딜)펜틸 이소펜틸 술폰인 화합물.
  10. 제1항에 있어서, 화합물이 2-(1-피페리딜)프로필 이소펜틸 술피드인 화합물.
  11. 제1항에 있어서, 화합물이 2-(1-피페리딜)에틸 에틸 술피드인 화합물.
  12. 환자에게 항진균성 유효량의 하기 일반식의 화합물을 투여하는 것으로 이루어지는, 진균의 감염으로 고생하는 환자를 치료하는 방법.
    상기 식 중 Y는 산소원자, 황원자, 술피닐기 또는 술포닐기이고, A는 0 내지 3개의 이중결합을 갖는 C2-C15알킬기이며, B는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이고, v는 정수 0,1 또는 2이며, R은 히드록시가, C1-C4알킬기 또는 하기식의 기
    (여기서, n은 정수 0,1,2 또는 3이고, R1, R2및 R3은 각각 독립적으로 수소원자 또는 C1-C4알킬기임)이다.
  13. 하기 일반식(2)의 화합물을 염기의 존재하에 하기 일반식(3)의 피페리딘 화합물과 반응시키는 것으로 이루어지는 하기 일반식(1)의 화합물의 제조방법.
    상기 식 중 Y는 산소원자, 황원자, 술피닐기 또는 술포닐기이고, A는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이며, B는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이고, v는 정수 0,1 또는 2이며, R은 히드록시가, C1-C4알킬기 또는 하기식의 기
    (여기서, n은 정수 0,1,2 또는 3이고, R1, R2및 R3은 각각 독립적으로 수소원자 또는 C1-C4알킬기임)이다.
  14. 하기 일반식(4)의 화합물을 환원시키는 것으로 이루어지는 하기 일반식(1)의 화합물의 제조방법.
    상기 식 중 Y는 산소원자, 황원자, 술피닐기 또는 술포닐기이고, A는 0 내지 3개의 이중결합을 갖는 C2-C15알킬렌기이며, B는 0 내지 5개의 이중결합을 갖는 C2-C15알킬기이고, v는 정수 0,1 또는 2이며, R은 하기식의 기
    (여기서, n은 정수 0,1,2 또는 3이고, R1, R2및 R3은 각각 독립적으로 수소원자 또는 C1-C4알킬기임)이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910012672A 1990-07-25 1991-07-24 콜레스테롤 생합성 억제제로서의 신규 피페리딜 에테르 및 티오에테르 KR100225764B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55787790A 1990-07-25 1990-07-25
US557,877 1990-07-25

Publications (2)

Publication Number Publication Date
KR920002539A true KR920002539A (ko) 1992-02-28
KR100225764B1 KR100225764B1 (ko) 1999-10-15

Family

ID=24227242

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910012672A KR100225764B1 (ko) 1990-07-25 1991-07-24 콜레스테롤 생합성 억제제로서의 신규 피페리딜 에테르 및 티오에테르

Country Status (17)

Country Link
EP (1) EP0468434B1 (ko)
JP (1) JP3387513B2 (ko)
KR (1) KR100225764B1 (ko)
CN (1) CN1058399A (ko)
AT (1) ATE134626T1 (ko)
AU (1) AU644458B2 (ko)
CA (1) CA2047375C (ko)
DE (1) DE69117375T2 (ko)
ES (1) ES2086436T3 (ko)
FI (1) FI913556A (ko)
HU (1) HUT58290A (ko)
IE (1) IE912613A1 (ko)
IL (1) IL98917A0 (ko)
NO (1) NO912888L (ko)
NZ (1) NZ239022A (ko)
PT (1) PT98437A (ko)
ZA (1) ZA915659B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348964A (en) * 1990-07-25 1994-09-20 Merrell Dow Pharmaceuticals Inc. Piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis
US5350758A (en) * 1992-07-08 1994-09-27 Merrell Dow Pharmaceuticals Inc. Piperidyl sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis
DE4303840A1 (de) * 1992-10-22 1994-08-11 Thomae Gmbh Dr K Aryliden-1-azacycloalkane und Arylalkyl-1-azacycloalkane, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
US5466687A (en) * 1992-10-22 1995-11-14 Dr. Karl Thomae Gmbh Arylidene-1-azacycloalkanes and arylalkyl-1-azacyclo-alkanes, their salts, medicaments containing these compounds and their use, and processes for their preparation
FR2697250B1 (fr) * 1992-10-28 1995-01-20 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique.
DE19754795A1 (de) * 1997-12-10 1999-06-17 Boehringer Ingelheim Pharma Neue Urethane, ihre Thio- und Dithioanaloga, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
AU7446900A (en) 1999-09-28 2001-04-30 Nihon Nohyaku Co., Ltd. Thioalkylamine derivatives and process for the preparation thereof
JP2001163854A (ja) * 1999-09-28 2001-06-19 Nippon Nohyaku Co Ltd チオアルキルアミン誘導体及びその製造方法
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
RU2010128543A (ru) 2007-12-11 2012-01-20 Сайтопатфайндер, Инк. (Jp) Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN113574055A (zh) 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3382180A (en) * 1958-04-01 1968-05-07 Lever Brothers Ltd Detergent compositions containing sulfoxide as a suds-stabilizing agent
US4244963A (en) * 1979-09-27 1981-01-13 Merck & Co., Inc. 1-[2-(Alkyl and arylsulfonyl)-2-propenyl and propyl] substituted piperidines useful as antimicrobial and antiinflammatory agents
US5149524A (en) * 1991-01-03 1992-09-22 Rohm And Haas Company Antimicrobial polymeric quaternary ammonium salts

Also Published As

Publication number Publication date
ATE134626T1 (de) 1996-03-15
PT98437A (pt) 1992-05-29
HUT58290A (en) 1992-02-28
NZ239022A (en) 1993-11-25
EP0468434A1 (en) 1992-01-29
FI913556A (fi) 1992-01-26
EP0468434B1 (en) 1996-02-28
DE69117375D1 (de) 1996-04-04
JP3387513B2 (ja) 2003-03-17
AU8119491A (en) 1992-01-30
FI913556A0 (fi) 1991-07-24
ES2086436T3 (es) 1996-07-01
CA2047375A1 (en) 1992-01-26
KR100225764B1 (ko) 1999-10-15
NO912888L (no) 1992-01-27
HU912486D0 (en) 1991-12-30
NO912888D0 (no) 1991-07-24
AU644458B2 (en) 1993-12-09
CA2047375C (en) 2003-04-15
JPH04234362A (ja) 1992-08-24
ZA915659B (en) 1992-05-27
CN1058399A (zh) 1992-02-05
IL98917A0 (en) 1992-07-15
DE69117375T2 (de) 1996-08-14
IE912613A1 (en) 1992-01-29

Similar Documents

Publication Publication Date Title
KR920002539A (ko) 콜레스테롤 생합성 억제제로서의 신규 피페리딜 에테르 및 티오에테르
KR930701402A (ko) N- 하이드로 카르빌 -4- 치환된 피페리딘, 이들의 제조 방법 및 이들의 칼슘 차단제로서의 용도
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
KR900006318A (ko) 피페리디닐 벤즈이미다졸
KR970701722A (ko) 포스폰산 디에스테르 유도체(phosphonic diester derivative)
KR920014772A (ko) 방사선 방호제로 유용한 폴리아민 티올
KR950010892A (ko) 자궁 섬유증 억제 방법
KR910011812A (ko) 염증성 장 질환 치료용 화합물
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR890003691A (ko) 피페리딘 유도체 및 그를 함유하는 부정맥을 위한 치료예방제
KR910019632A (ko) 비스(알킬-치환-4-히드록시페닐티오)알칸 유사체를 유효성분으로 함유하는 백내장 발병 억제용 제약 조성물
ATE341319T1 (de) Esmolol-enthaltende zubereitungen
KR880002827A (ko) 칼슘 효능 활성 및 α₁-길항 활성이 있는 1,4-디하이드로 피리딘 유도체
KR950702534A (ko) 콜레스테롤 생합성 억제제로서의 신규한 피페리딜 아미드, 설폰아미드 및 설폭스아미드(Novel piperidyl amides, sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis)
KR910016660A (ko) 스쿠알렌 에폭시다제 억제제로서의 스쿠알렌의 디-및 테트라-플루오르 유사체
KR900018027A (ko) 피페리딘 유도체, 그의 제조 방법, 및 그것을 유효성분으로 함유하는 의약용 조성물
KR860008973A (ko) 2-피롤리돈 유도체
FR2803593B1 (fr) Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
KR960003719A (ko) 녹내장 치료제 및 안압 강하제
EP1142883A4 (en) HETEROCYCLIC COMPOUNDS AND MEDICINAL COMPOSITIONS THAT CONTAIN THEM
KR910002456A (ko) 당뇨병 치료용 제약 조성물
SE8300855L (sv) Nya piperazin- och homopiperazinderivat, forfaranden for framstellning derav och farmaceutiska kompositioner innehallande dem
DK0485219T3 (da) Lægemidler til forebyggelse og behandling af kredsløbsorgansygdomme indeholdende spiro-3-heteroazolidinforbindelser

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020716

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee